The NHS announced a new injectable form of pembrolizumab, a cancer immunotherapy, which is projected to save the public health system over 100,000 hours of preparation and treatment time each year, while pharmaceutical corporations continue to extract profits from life-saving medical advancements. This efficiency gain for the NHS, a state-managed healthcare system, translates into reduced operational costs, indirectly benefiting the fiscal health of the state which primarily serves to protect accumulated wealth. The development and sale of such drugs remain under the control of private pharmaceutical capital.
The new injectable form of pembrolizumab can be administered in under two minutes, a stark contrast to the previous intravenous drip method which required approximately two hours per session for patients and was described as time-consuming and expensive for NHS staff to maintain. Most of the 14,000 patients already receiving pembrolizumab are expected to transition to the new injectable version, which will be given every three weeks as a one-minute injection or every six weeks as a two-minute injection.
Efficiency for the State, Profit for Capital
Prof Peter Johnson, the NHS national clinical director for cancer, stated that this innovation would help "free up vital appointments for NHS teams to treat more people and continue to bring down waiting times," framing a technological fix as the solution to systemic underfunding and capacity issues within public healthcare. This approach manages the contradictions of a public health system operating under capitalist constraints, rather than challenging the profit motives of pharmaceutical companies or advocating for increased public investment.
James Richardson, national specialty adviser for cancer drugs at NHS England, characterized the development as a "win-win innovation" that provides clinical teams with "more capacity to care for others." This rhetoric reinforces the idea that efficiency adjustments within the existing system are sufficient to address healthcare crises, diverting attention from the structural issues that create these crises. The "time saved through this change is a huge gain for the NHS," according to Richardson, highlighting the state's focus on cost-saving within its public services.
The Burden on Labor and Patients
The previous method's burden on NHS staff, described as "time-consuming and expensive to maintain," underscores the constant pressure on healthcare labor within an underfunded system. The new jab offers a reprieve from this specific inefficiency, but does not address the broader conditions of wage suppression or overwork that often characterize public sector employment.
For patients, the shift to a rapid injection alleviates the physical and temporal burden of treatment. Shirley Xerxes, an 89-year-old patient, highlighted the personal impact, reporting she was "only in the chair for a matter of minutes instead of an hour or more," which she said "gives me more time to live my life, including spending more time gardening." This individual relief, while significant, does not alter the fundamental commodification of healthcare.
Managing Contradictions, Not Challenging Power
This new treatment follows the availability of nivolumab, another immunotherapy injection taking three to five minutes to administer, which became eligible for up to 15,000 cancer patients one year ago. With the addition of this new treatment, the NHS now offers two immunotherapies for almost 30 types of cancer. This selective availability demonstrates how advancements, while beneficial to some, are introduced incrementally within the existing market logic, rather than as part of a comprehensive, universally accessible healthcare strategy.
The drug itself functions by killing cancer cells through blocking a protein called PD-1, which acts as a brake on immune responses, thereby allowing the immune system to recognize and attack cancer cells. University hospitals Bristol and Weston NHS foundation trust and East and North Hertfordshire teaching NHS trust are among the first institutions in England to provide the treatment, integrating this new technology into the existing healthcare infrastructure without altering its core economic foundations.